$LLY · Eli Lilly and Company
Latest call · 2026-04-29
The call
Head-to-head · Claude vs the Street vs reality
| Claude | Street | Actual | |
|---|---|---|---|
| EPS | $7.50 | $7.26 | ⏳ pending |
| Revenue | $18.10B | $17.78B | — |
| Direction (1d) | 🟢 UP |
🟢 UP
23B · 6H · 1S
|
— |
| 1d move | +4.0% | — | — |
| 3d move | +6.0% | — | — |
Thesis
Lilly comes in -20% YTD with RSI 33 oversold and the bear narrative ('losing the GLP-1 race', Canada generic) fully entrenched — textbook hype_washed_out. Symphony/IQVIA prescription trackers show Mounjaro/Zepbound Q1 fill volumes accelerating, and the Foundayo oral GLP-1 approval is a 2027-pulled-forward catalyst most models haven't fully captured. Spot at $853 vs $1242 PT leaves enormous cushion.
What would flip it
A Mounjaro/Zepbound Q1 revenue miss vs Street would crystallize the GLP-1-saturation bear thesis and trigger a -5 to -7% capitulation.
The market's narrative
RSI 33 oversold, YTD -20.56%, HSBC Reduce + Canada-Ozempic-generic = bear narrative entrenched; 12mo target $1242 implies +45% upside; Mounjaro/Zepbound now 56% of sales growing to >60%; oral GLP-1 Foundayo recently approved.
Where the Street may be wrong
- Mounjaro/Zepbound prescription tracker (Symphony, IQVIA) shows Q1 fill volumes accelerating despite Canada generic noise — US/EU markets are the dominant revenue driver and were unaffected.
- Foundayo (oral GLP-1) approval is a structural compound-the-franchise positive — most models still treat it as a 2027 contributor, not 2026 H2.
- Manufacturing capacity additions (Indianapolis, RTP) are coming online faster than 2025 supply-constraint base case — Q1 gross margin should hold mid-80s vs Street modeling 81-82%.
Peer read: NVO Q1 comps later in earnings season — LLY is the lead read for the GLP-1 cohort. CVS PBM commentary on weight-loss formularies has been constructive on margin pass-through.
Reasoning
- Hype_washed_out template per 04-23 TSLA lesson: YTD -20.56% (deep double-digit) + RSI 33 oversold + terminal-language press ('Lilly losing the GLP-1 race') = textbook setup.
- Q1 EPS expected +117% YoY — a clean beat on this growth bar drives a CMCSA-style washed-out + operational-metric (Mounjaro $$ growth) squeeze.
- Spot $853 vs target $1242 = 45% upside; analyst PT cushion supports a 4-6% pop without breaking framework.
- Foundayo approval is a 2027-pulled-forward catalyst that buy-side hasn't fully marked into models.
- Apply 04-29 lesson: washed-out + structural-overhang lift (oral GLP-1 approval) + raised guide on operational-metric beat = +5-8% magnitude band.
Risks to the call
- Mounjaro/Zepbound Q1 revenue MISS vs Street consensus would crystallize the 'GLP-1 saturation' bear thesis — flips this to -5 to -7% capitulation.
- Foundayo launch costs front-loaded into Q2 guide could trim near-term EPS visibility, capping upside at +1-2%.